Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.49 |
| ▸ | GNPAT | O15228 | 1/20 | 0.49 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.47 |
| ▸ | FNTA | P49354 | 3/20 | 0.44 |
| ▸ | FNTB | P49356 | 3/20 | 0.44 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.42 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.39 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4649464 | 1.00 | SLC6A5 (0.51) | SLC6A5FOLH1GNPATNOD1FNTA | |
| SCHEMBL4648005 | 0.93 | SLC6A5 (0.59) | SLC6A5FOLH1GNPATNOD1FNTA | |
| SCHEMBL18807817 | 0.93 | SLC6A5 (0.59) | SLC6A5FOLH1GNPATNOD1FNTA | |
| SCHEMBL14854309 | 0.93 | SLC6A5 (0.59) | SLC6A5FOLH1GNPATNOD1FNTA | |
| SCHEMBL14854318 | 0.93 | SLC6A5 (0.59) | SLC6A5FOLH1GNPATNOD1FNTA | |
| SCHEMBL16187733 | 0.93 | SLC6A5 (0.59) | SLC6A5FOLH1GNPATNOD1FNTA | |
| SCHEMBL16187738 | 0.93 | SLC6A5 (0.59) | SLC6A5FOLH1GNPATNOD1FNTA | |
| SCHEMBL16187737 | 0.93 | SLC6A5 (0.59) | SLC6A5FOLH1GNPATNOD1FNTA | |
| SCHEMBL16187739 | 0.93 | SLC6A5 (0.59) | SLC6A5FOLH1GNPATNOD1FNTA | |
| SCHEMBL14854345 | 0.93 | SLC6A5 (0.59) | SLC6A5FOLH1GNPATNOD1FNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080292547-A1 | Novel Imaging Agents for Fibrosis | TOLLESHAUG HELGE | 2008-11-27 | — | — | US | claimed |
| EP-1962911-A2 | NOVEL IMAGING AGENTS FOR FIBROSIS | GE Healthcare Limited (GB) | 2008-09-03 | — | — | EP | claimed |
| WO-2007066119-A2 | NOVEL IMAGING AGENTS FOR FIBROSIS | GE HEALTHCARE LIMITED (GB) | 2007-06-14 | — | — | WO | claimed |
| WO-1996040746-A1 | LYSYLOXIDASE INHIBITORS | TRUSTEES OF BOSTON UNIVERSITY (US) | 1996-12-19 | — | — | WO | claimed |
| US-20080292547-A1 | Novel Imaging Agents for Fibrosis | TOLLESHAUG HELGE | 2008-11-27 | — | — | US | disclosed |
| EP-1962911-A2 | NOVEL IMAGING AGENTS FOR FIBROSIS | GE Healthcare Limited (GB) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007066119-A2 | NOVEL IMAGING AGENTS FOR FIBROSIS | GE HEALTHCARE LIMITED (GB) | 2007-06-14 | — | — | WO | disclosed |
| WO-1996040746-A1 | LYSYLOXIDASE INHIBITORS | TRUSTEES OF BOSTON UNIVERSITY (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080292547-A1 | Novel Imaging Agents for Fibrosis | LOXL1, LOXL2, LOXL3 | SLC6A5 2887/4885FOLH1 1072/4885GNPAT 2508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.